BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 11904986)

  • 1. [Molecular target-based cancer therapy: epidermal growth factor receptor inhibitors].
    Tamura T
    Nihon Geka Gakkai Zasshi; 2002 Feb; 103(2):233-6. PubMed ID: 11904986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor inhibition strategies in oncology.
    Harari PM
    Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor as a therapeutic target in colorectal cancer.
    Cohen RB
    Clin Colorectal Cancer; 2003 Feb; 2(4):246-51. PubMed ID: 12620146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor as a target for chemotherapy.
    Vallbohmer D; Lenz HJ
    Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S19-27. PubMed ID: 15871762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
    Karamouzis MV; Grandis JR; Argiris A
    JAMA; 2007 Jul; 298(1):70-82. PubMed ID: 17609492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic implications of epidermal growth factor receptor in lung cancer].
    Fayette J; Le Chevalier T; Soria JC
    Bull Cancer; 2003 Nov; 90 Spec No():S233-40. PubMed ID: 14763145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The epidermal growth factor receptor pathway and its inhibition as anticancer therapy.
    Janmaat ML; Giaccone G
    Drugs Today (Barc); 2003; 39 Suppl C():61-80. PubMed ID: 14988746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer.
    Bunn PA; Franklin W
    Semin Oncol; 2002 Oct; 29(5 Suppl 14):38-44. PubMed ID: 12422312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.
    Blackledge G; Averbuch S
    Br J Cancer; 2004 Feb; 90(3):566-72. PubMed ID: 14760365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.
    Ciardiello F; De Vita F; Orditura M; De Placido S; Tortora G
    Expert Opin Emerg Drugs; 2003 Nov; 8(2):501-14. PubMed ID: 14662002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor-targeted therapy in colorectal cancer.
    O'dwyer PJ; Benson AB
    Semin Oncol; 2002 Oct; 29(5 Suppl 14):10-7. PubMed ID: 12422309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I studies of ZD1839 in patients with common solid tumors.
    Lorusso PM
    Semin Oncol; 2003 Feb; 30(1 Suppl 1):21-9. PubMed ID: 12644981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial growth factor receptor interacting agents.
    Baselga J; Albanell J
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1041-63. PubMed ID: 12512382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The epidermal growth factor receptor as a target for colorectal cancer therapy.
    Lockhart AC; Berlin JD
    Semin Oncol; 2005 Feb; 32(1):52-60. PubMed ID: 15726506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer.
    Tiseo M; Loprevite M; Ardizzoni A
    Curr Med Chem Anticancer Agents; 2004 Mar; 4(2):139-48. PubMed ID: 15032719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
    Ciardiello F; Tortora G
    Clin Cancer Res; 2001 Oct; 7(10):2958-70. PubMed ID: 11595683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.